Login Register Cart 0
Generic placeholder image

Current Genomics

Editor-in-Chief

ISSN (Print): 1389-2029
ISSN (Online): 1875-5488

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Repurposing Pathogenic Variants of DMD Gene and its Isoforms for DMD Exon Skipping Intervention

Author(s): Rahul Tyagi, Sumit Kumar, Ashwin Dalal, Faruq Mohammed, Manju Mohanty, Paramvir Kaur and Akshay Anand *

Volume 20, Issue 7, 2019

Page: [519 - 530] Pages: 12

DOI: 10.2174/1389202920666191107142754

Price: $65

Abstract

Background: Duchenne Muscular Dystrophy (DMD) is a progressive, fatal neuromuscular disorder caused by mutations in the DMD gene. Emerging antisense oligomer based exon skipping therapy provides hope for the restoration of the reading frame.

Objectives: Population-based DMD mutation database may enable exon skipping to be used for the benefit of patients. Hence, we planned this study to identify DMD gene variants in North Indian DMD cases.

Methods: A total of 100 DMD cases were recruited and Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to obtain the deletion and duplication profile.

Results: Copy number variations (deletion/duplication) were found in 80.85% of unrelated DMD cases. Sixty-eight percent of cases were found to have variations in the distal hotspot region (Exon 45- 55) of the DMD gene. Exon 44/45 variations were found to be the most prominent among single exon variations, whereas exon 49/50 was found to be the most frequently mutated locations in single/ multiple exon variations. As per Leiden databases, 86.84% cases harboured out-of-frame mutations. Domain wise investigation revealed that 68% of mutations were localized in the region of spectrin repeats. Dp140 isoform was predicted to be absent in 62/76 (81.57%) cases. A total of 45/80 (56.25 %) and 23/80 (28.70%) DMD subjects were predicted to be amenable to exon 51 and exon 45 skipping trials, respectively.

Conclusion: A major proportion of DMD subjects (80%) could be diagnosed by the MLPA technique. The data generated from our study may be beneficial for strengthening of mutation database in the North Indian population.

Keywords: Duchenne Muscular Dystrophy (DMD), dystrophin, exon skipping, MLPA, pathogenic variants, neuromuscular disorder.

« Previous Next »
Graphical Abstract

[1]
Hoffman, E.P.; Brown, R.H., Jr; Kunkel, L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 1987, 51(6), 919-928.
[http://dx.doi.org/10.1016/0092-8674(87)90579-4] [PMID: 3319190]
[2]
Petrof, B.J.; Shrager, J.B.; Stedman, H.H.; Kelly, A.M.; Sweeney, H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA, 1993, 90(8), 3710-3714.
[http://dx.doi.org/10.1073/pnas.90.8.3710] [PMID: 8475120]
[3]
Mercuri, E.; Muntoni, F. Muscular dystrophies. Lancet, 2013, 381(9869), 845-860.
[http://dx.doi.org/10.1016/S0140-6736(12)61897-2] [PMID: 23465426]
[4]
Nudel, U.; Zuk, D.; Einat, P.; Zeelon, E.; Levy, Z.; Neuman, S.; Yaffe, D. Duchenne muscular dystrophy gene product is not identical in muscle and brain. Nature, 1989, 337(6202), 76-78.
[http://dx.doi.org/10.1038/337076a0] [PMID: 2909892]
[5]
Holder, E.; Maeda, M.; Bies, R.D. Expression and regulation of the dystrophin Purkinje promoter in human skeletal muscle, heart, and brain. Hum. Genet., 1996, 97(2), 232-239.
[http://dx.doi.org/10.1007/BF02265272] [PMID: 8566960]
[6]
D’Souza, V.N.; Nguyen, T.M.; Morris, G.E.; Karges, W.; Pillers, D.A.; Ray, P.N. A novel dystrophin isoform is required for normal retinal electrophysiology. Hum. Mol. Genet., 1995, 4(5), 837-842.
[http://dx.doi.org/10.1093/hmg/4.5.837] [PMID: 7633443]
[7]
Byers, T.J.; Lidov, H.G.; Kunkel, L.M. An alternative dystrophin transcript specific to peripheral nerve. Nat. Genet., 1993, 4(1), 77-81.
[http://dx.doi.org/10.1038/ng0593-77] [PMID: 8513330]
[8]
Bardoni, A.; Felisari, G.; Sironi, M.; Comi, G.; Lai, M.; Robotti, M.; Bresolin, N. Loss of Dp140 regulatory sequences is associated with cognitive impairment in dystrophinopathies. Neuromuscul. Disord., 2000, 10(3), 194-199.
[http://dx.doi.org/10.1016/S0960-8966(99)00108-X] [PMID: 10734267]
[9]
Simanti, B.A.D.; Angshuman, B. Domain wise distribution of mutations in dystrophin protein and duchenne muscular dystrophy. Gene Technol., 2015, 4(3), 128.
[10]
Chamberlain, J.S.; Gibbs, R.A.; Ranier, J.E.; Nguyen, P.N.; Caskey, C.T. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res., 1988, 16(23), 11141-11156.
[http://dx.doi.org/10.1093/nar/16.23.11141] [PMID: 3205741]
[11]
Chamberlain, J. S. Multiplex PCR for diagnosis of Duchenne muscular dystrophy. PCR protocols: a guide to methods and applications, 1990, 272.
[http://dx.doi.org/10.1016/B978-0-12-372180-8.50037-8]
[12]
Beggs, A.H.; Koenig, M.; Boyce, F.M.; Kunkel, L.M. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum. Genet., 1990, 86(1), 45-48.
[http://dx.doi.org/10.1007/BF00205170] [PMID: 2253937]
[13]
Kunkel, L.; Snyder, J.; Beggs, A.; Boyce, F.; Feener, C. Searching for dystrophin gene deletions in patients with atypical presentations. Etiology of human disease at the DNA level; Raven: New York, 1991, pp. 51-60.
[14]
Schouten, J.P.; McElgunn, C.J.; Waaijer, R.; Zwijnenburg, D.; Diepvens, F.; Pals, G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res., 2002, 30(12) e57
[http://dx.doi.org/10.1093/nar/gnf056] [PMID: 12060695]
[15]
Vorstman, J.A.; Jalali, G.R.; Rappaport, E.F.; Hacker, A.M.; Scott, C.; Emanuel, B.S. MLPA: a rapid, reliable, and sensitive method for detection and analysis of abnormalities of 22q. Hum. Mutat., 2006, 27(8), 814-821.
[http://dx.doi.org/10.1002/humu.20330] [PMID: 16791841]
[16]
Murugan, S.; Chandramohan, A.; Lakshmi, B.R. Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis. Indian J. Med. Res., 2010, 132, 303-311.
[PMID: 20847377]
[17]
Lalic, T.; Vossen, R.H.; Coffa, J.; Schouten, J.P.; Guc-Scekic, M.; Radivojevic, D.; Djurisic, M.; Breuning, M.H.; White, S.J.; den Dunnen, J.T. Deletion and duplication screening in the DMD gene using MLPA. Eur. J. Hum. Genet., 2005, 13(11), 1231-1234.
[http://dx.doi.org/10.1038/sj.ejhg.5201465] [PMID: 16030524]
[18]
Dastur, R.S.; Kachwala, M.Y.; Khadilkar, S.V.; Hegde, M.R.; Gaitonde, P.S. Identification of deletions and duplications in the Duchenne muscular dystrophy gene and female carrier status in western India using combined methods of multiplex polymerase chain reaction and multiplex ligation-dependent probe amplification. Neurol. India, 2011, 59(6), 803-809.
[http://dx.doi.org/10.4103/0028-3886.91355] [PMID: 22234189]
[19]
Nalini, A.; Polavarapu, K.; Preethish-Kumar, V. Muscular dystrophies: An Indian scenario. Neurol. India, 2017, 65(5), 969-970.
[http://dx.doi.org/10.4103/neuroindia.NI_733_17] [PMID: 28879877]
[20]
Aartsma-Rus, A.; Ginjaar, I.B.; Bushby, K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J. Med. Genet., 2016, 53(3), 145-151.
[http://dx.doi.org/10.1136/jmedgenet-2015-103387]
[21]
Bladen, C.L.; Salgado, D.; Monges, S.; Foncuberta, M.E.; Kekou, K.; Kosma, K.; Dawkins, H.; Lamont, L.; Roy, A.J.; Chamova, T.; Guergueltcheva, V.; Chan, S.; Korngut, L.; Campbell, C.; Dai, Y.; Wang, J.; Barišić, N.; Brabec, P.; Lahdetie, J.; Walter, M.C.; Schreiber-Katz, O.; Karcagi, V.; Garami, M.; Viswanathan, V.; Bayat, F.; Buccella, F.; Kimura, E.; Koeks, Z.; van den Bergen, J.C.; Rodrigues, M.; Roxburgh, R.; Lusakowska, A.; Kostera-Pruszczyk, A.; Zimowski, J.; Santos, R.; Neagu, E.; Artemieva, S.; Rasic, V.M.; Vojinovic, D.; Posada, M.; Bloetzer, C.; Jeannet, P.Y.; Joncourt, F.; Díaz-Manera, J.; Gallardo, E.; Karaduman, A.A.; Topaloğlu, H.; El Sherif, R.; Stringer, A.; Shatillo, A.V.; Martin, A.S.; Peay, H.L.; Bellgard, M.I.; Kirschner, J.; Flanigan, K.M.; Straub, V.; Bushby, K.; Verschuuren, J.; Aartsma-Rus, A.; Béroud, C.; Lochmüller, H. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat., 2015, 36(4), 395-402.
[http://dx.doi.org/10.1002/humu.22758] [PMID: 25604253]
[22]
Polavarapu, K.; Preethish-Kumar, V.; Sekar, D.; Vengalil, S.; Nashi, S.; Mahajan, N.P.; Thomas, P.T.; Sadasivan, A.; Warrier, M.; Gupta, A.; Arunachal, G.; Debnath, M.; Keerthipriya, M.S.; Pradeep-Chandra-Reddy, C.; Puttegowda, A.; John, A.P.; Tavvala, A.; Gunasekaran, S.; Sathyaprabha, T.N.; Chandra, S.R.; Kramer, B.; Delhaas, T.; Nalini, A. Mutation pattern in 606 Duchenne muscular dystrophy children with a comparison between familial and non-familial forms: a study in an Indian large single-center cohort. J. Neurol., 2019, 266(9), 2177-2185.
[http://dx.doi.org/10.1007/s00415-019-09380-3] [PMID: 31139960]
[23]
Ricotti, V.; Jägle, H.; Theodorou, M.; Moore, A.T.; Muntoni, F.; Thompson, D.A. Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system. Eur. J. Hum. Genet., 2016, 24(4), 562-568.
[http://dx.doi.org/10.1038/ejhg.2015.135] [PMID: 26081639]
[24]
Koenig, M.; Hoffman, E.P.; Bertelson, C.J.; Monaco, A.P.; Feener, C.; Kunkel, L.M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 1987, 50(3), 509-517.
[http://dx.doi.org/10.1016/0092-8674(87)90504-6] [PMID: 3607877]
[25]
Den Dunnen, J.T.; Grootscholten, P.M.; Bakker, E.; Blonden, L.A.; Ginjaar, H.B.; Wapenaar, M.C.; van Paassen, H.M.; van Broeckhoven, C.; Pearson, P.L.; van Ommen, G.J. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am. J. Hum. Genet., 1989, 45(6), 835-847.
[PMID: 2573997]
[26]
Wang, X.; Wang, Z.; Yan, M.; Huang, S.; Chen, T-J.; Zhong, N. Similarity of DMD gene deletion and duplication in the Chinese patients compared to global populations. Behav. Brain Funct., 2008, 4(1), 20.
[http://dx.doi.org/10.1186/1744-9081-4-20] [PMID: 18445268]
[27]
Lai, P-S.; Takeshima, Y.; Adachi, K.; van Tran, K.; Nguyen, H. T.; Low, P. -S.; Matsuo, M. Comparative study on deletions of the dystrophin gene in three Asian populations. J. Human Genetics, 2002, 47(10), pp. 0552-0555.
[28]
Swaminathan, B.; Shubha, G.N.; Shubha, D.; Murthy, A.R.; Kiran Kumar, H.B.; Shylashree, S.; Gayathri, N.; Jamuna, R.; Jain, S.; Purushottam, M.; Nalini, A. Duchenne muscular dystrophy: a clinical, histopathological and genetic study at a neurology tertiary care center in Southern India. Neurol. India, 2009, 57(6), 734-738.
[http://dx.doi.org/10.4103/0028-3886.59468] [PMID: 20139501]
[29]
Basak, J.; Dasgupta, U.B.; Mukherjee, S.C.; Das, S.K.; Senapati, A.K.; Banerjee, T.K. Deletional mutations of dystrophin gene and carrier detection in eastern India. Indian J. Pediatr., 2009, 76(10), 1007-1012.
[http://dx.doi.org/10.1007/s12098-009-0214-y] [PMID: 19907931]
[30]
Vengalil, S.; Preethish-Kumar, V.; Polavarapu, K.; Mahadevappa, M.; Sekar, D.; Purushottam, M.; Thomas, P.T.; Nashi, S.; Nalini, A. Duchenne muscular dystrophy and becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: genotype-phenotype correlation in a large cohort. J. Clin. Neurol., 2017, 13(1), 91-97.
[http://dx.doi.org/10.3988/jcn.2017.13.1.91] [PMID: 28079318]
[31]
Prior, T.W.; Bridgeman, S.J. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. J. Mol. Diagn., 2005, 7(3), 317-326.
[http://dx.doi.org/10.1016/S1525-1578(10)60560-0] [PMID: 16049303]
[32]
Lee, B.L.; Nam, S.H.; Lee, J.H.; Ki, C.S.; Lee, M.; Lee, J. Genetic analysis of dystrophin gene for affected male and female carriers with Duchenne/Becker muscular dystrophy in Korea. J. Korean Med. Sci., 2012, 27(3), 274-280.
[http://dx.doi.org/10.3346/jkms.2012.27.3.274] [PMID: 22379338]
[33]
Yotova, V.; Lefebvre, J.F.; Moreau, C.; Gbeha, E.; Hovhannesyan, K.; Bourgeois, S.; Bédarida, S.; Azevedo, L.; Amorim, A.; Sarkisian, T.; Avogbe, P.H.; Chabi, N.; Dicko, M.H.; Kou’ Santa Amouzou, E.S.; Sanni, A.; Roberts-Thomson, J.; Boettcher, B.; Scott, R.J.; Labuda, D. An X-linked haplotype of Neandertal origin is present among all non-African populations. Mol. Biol. Evol., 2011, 28(7), 1957-1962.
[http://dx.doi.org/10.1093/molbev/msr024] [PMID: 21266489]
[34]
Ballo, R.; Viljoen, D.; Beighton, P. Duchenne and Becker muscular dystrophy prevalence in South Africa and molecular findings in 128 persons affected. S. Afr. Med. J., 1994, 84(8 Pt 1), 494-497.
[PMID: 7825085]
[35]
Mendell, J.R.; Sahenk, Z.; Rodino-Klapac, L.R. Clinical trials of exon skipping in Duchenne muscular dystrophy. Expert Opin. Orphan Drugs, 2017, 5(9), 683-690.
[http://dx.doi.org/10.1080/21678707.2017.1366310]
[36]
Aartsma-Rus, A.; Krieg, A.M. FDA approves eteplirsen for duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Therapeutics, 2017, 27(1), 1-3.
[37]
Echigoya, Y.; Yokota, T. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther., 2014, 24(1), 57-68.
[http://dx.doi.org/10.1089/nat.2013.0451] [PMID: 24380394]
[38]
Zhu, Y.; Gan, J.; Luo, J.; Zheng, X.; Wei, S.; Hu, D. Splicing mutation of a gene within the Duchenne muscular dystrophy family. Genetics Mol Res: GMR, 2016, 15(2)
[http://dx.doi.org/10.4238/gmr.15028258]

Rights & Permissions Print Cite
Article Metrics
12
1
© 2024 Bentham Science Publishers | Privacy Policy